(VIANEWS) – Cronos Group (NASDAQ: CRON) shares witnessed a 12.35% gain to EUR2.53 at 14:01 EST on Wednesday, after slumping 16.90% the previous session. This outperformed the wider market; which saw only 0.5% growth. Cronos is currently trading 37.78% below its 52-week high of EUR3.62.
About Cronos Group
Cronos Group Inc. is a cannabinoid company which manufactures, markets and distributes hemp-derived supplements and cosmetic products in the US under their Lord Jones brand. Additionally, they cultivate, manufacture and market cannabis-derived products for medical and adult-use markets under PEACE NATURALS’ wellness platform and under their adult-use brands, Spinach. Cronos Group was established in 2012 in Toronto Canada.
Yearly Analysis
Cronos Group (CRON) currently trades at EUR2.53, significantly below its 52-week high of EUR3.62 but higher than its 52-week low of EUR1.64; this indicates a decline over the past year which may now be making progress toward recovery.
Cronos Group’s sales growth is projected to experience a negative 12.2% decline this year and an anticipated rebound to 20% growth within one year, suggesting external factors may have negatively impacted its sales; but its sales should rebound within this year and beyond.
Cronos Group currently stands with an EBITDA value of -2.27, representing a negative cash flow. Investors should pay attention to how the company handles expenses and can improve financial performance over the coming months.
Cronos Group stock may offer investors willing to take on short-term risks for potential long-term gains an excellent investment opportunity. Anticipated sales growth and the potential of its financial performance improvement make this stock worth considering by those with a higher-risk tolerance; however, investors must do additional research and analyze other factors prior to making any definitive investment decisions.
Technical Analysis
Cronos Group’s stock is currently trading above both its 50-day and 200-day moving averages, signifying both short- and long-term bullish trends. Furthermore, its trading volume is significantly greater than usual, signalling high trading activity with potential strong buying interest.
Note, however, that the stock’s volatility has been relatively high over the past week, month and quarter; its average intraday variation being 6.29% for each of these timeframes respectively – suggesting its price movements have been relatively unpredictable and may remain so in the near future.
Stochastic oscillator indicates that the stock may be oversold (=20), suggesting it could be an ideal time to purchase. Before making any definitive investment decisions, however, other considerations such as company finances and industry trends must also be taken into account.
Quarter Analysis
Cronos Group currently reports negative 19.1% sales growth, which suggests a decline in revenue and is cause for alarm as this indicates their products are no longer selling as effectively as before. Fortunately, their estimated growth for both quarters are 80-90.5 % indicating they remain confident about increasing sales in near future.
Although revenue growth for the twelve trailing months is estimated to have fallen from its high of 86.1M in Q3 2018 to just 86.1M now, growth estimates suggest the company could possibly turn things around with new product releases, increased marketing initiatives or shifting market conditions.
Overall, investors should keep an eye on Cronos Group’s sales growth and revenue trends to assess whether their growth estimates are realistic and whether the company can increase sales soon. If Cronos Group can successfully expand sales, this could present investors with an excellent investment opportunity; otherwise if sales continue to decrease investors may wish to reconsider investing in it.
Equity Analysis
Cronos Group currently has an earnings per share (EPS) value of EUR-0.4, which indicates it is not producing profits at this time and should serve as a useful indicator for investors regarding its overall health and performance.
Negative returns on equity of -12.1% over twelve trailing months is cause for alarm as this suggests the company may not be making profits for shareholders relative to their equity investment. Furthermore, such an indication suggests the organization is failing to efficiently utilize assets for revenue generation purposes.
Investors should carefully review this data when making investment decisions and should also evaluate other financial metrics and analysis of company fundamentals. Seeking professional advice before taking any investments could also be wise.
More news about Cronos Group (CRON).
